Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. NVDA
6. IBM
7. PRIM
8. SPY
9. ACN
10. BLZE

Go back to Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Exelixis, Inc. (NASDAQ: EXEL) Delayed: 51.99 +0.64 (1.25%)
Previous Close $51.35    52 Week High $17.00 
Open $51.39    52 Week Low $3.55 
Day High $52.01    P/E N/A 
Day Low $50.88    EPS $-1.33 
Volume 1,163,560